Titre : Inhibiteurs de la cyclooxygénase 2

Inhibiteurs de la cyclooxygénase 2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Neural Cell Adhesion Molecule L1
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs de la cyclooxygénase 2 : Questions médicales les plus fréquentes", "headline": "Inhibiteurs de la cyclooxygénase 2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inhibiteurs de la cyclooxygénase 2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-12", "dateModified": "2025-04-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inhibiteurs de la cyclooxygénase 2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Inhibiteurs des cyclooxygénases", "url": "https://questionsmedicales.fr/mesh/D016861", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des cyclooxygénases", "code": { "@type": "MedicalCode", "code": "D016861", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.954.329.030.500" } } }, "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la cyclooxygénase 2", "alternateName": "Cyclooxygenase 2 Inhibitors", "code": { "@type": "MedicalCode", "code": "D052246", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Afshin Zarghi", "url": "https://questionsmedicales.fr/author/Afshin%20Zarghi", "affiliation": { "@type": "Organization", "name": "Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Rui Wang", "url": "https://questionsmedicales.fr/author/Rui%20Wang", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China." } }, { "@type": "Person", "name": "Mahsa Azami Movahed", "url": "https://questionsmedicales.fr/author/Mahsa%20Azami%20Movahed", "affiliation": { "@type": "Organization", "name": "Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Mohammad Mahboubi-Rabbani", "url": "https://questionsmedicales.fr/author/Mohammad%20Mahboubi-Rabbani", "affiliation": { "@type": "Organization", "name": "Islamic Azad University, Tehran Department of Medicinal Chemistry Tehran Iran." } }, { "@type": "Person", "name": "Ying Wang", "url": "https://questionsmedicales.fr/author/Ying%20Wang", "affiliation": { "@type": "Organization", "name": "College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Analysis of L1CAM gene mutation and imaging appearance in three Chinese families with L1 syndrome: Three case reports.", "datePublished": "2022-07-05", "url": "https://questionsmedicales.fr/article/35791503", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/mgg3.2002" } }, { "@type": "ScholarlyArticle", "name": "Novel duplication of the cell adhesion molecule L1-like gene in an individual with cognitive impairment, tall stature, and obesity: A case report.", "datePublished": "2023-04-11", "url": "https://questionsmedicales.fr/article/37114233", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fneur.2023.1104649" } }, { "@type": "ScholarlyArticle", "name": "Astrocyte-synapse interactions and cell adhesion molecules.", "datePublished": "2022-06-19", "url": "https://questionsmedicales.fr/article/35647709", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/febs.16540" } }, { "@type": "ScholarlyArticle", "name": "Increased expression of cell adhesion molecules in myofasciitis.", "datePublished": "2023-05-09", "url": "https://questionsmedicales.fr/article/37228411", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fneur.2023.1113404" } }, { "@type": "ScholarlyArticle", "name": "The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.", "datePublished": "2024-07-05", "url": "https://questionsmedicales.fr/article/38972089", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ygyno.2024.06.016" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Utilisations thérapeutiques", "item": "https://questionsmedicales.fr/mesh/D045506" }, { "@type": "ListItem", "position": 5, "name": "Antirhumatismaux", "item": "https://questionsmedicales.fr/mesh/D018501" }, { "@type": "ListItem", "position": 6, "name": "Anti-inflammatoires non stéroïdiens", "item": "https://questionsmedicales.fr/mesh/D000894" }, { "@type": "ListItem", "position": 7, "name": "Inhibiteurs des cyclooxygénases", "item": "https://questionsmedicales.fr/mesh/D016861" }, { "@type": "ListItem", "position": 8, "name": "Inhibiteurs de la cyclooxygénase 2", "item": "https://questionsmedicales.fr/mesh/D052246" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inhibiteurs de la cyclooxygénase 2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la cyclooxygénase 2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inhibiteurs de la cyclooxygénase 2", "description": "Comment diagnostiquer une inflammation nécessitant des COX-2 ?\nQuels tests sont utilisés pour évaluer l'efficacité des COX-2 ?\nLes COX-2 sont-ils prescrits pour toutes les douleurs ?\nComment différencier les douleurs inflammatoires des autres ?\nQuels signes cliniques indiquent l'utilisation des COX-2 ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Neural+Cell+Adhesion+Molecule+L1&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inhibiteurs de la cyclooxygénase 2", "description": "Quels symptômes traitent les inhibiteurs de COX-2 ?\nLes COX-2 soulagent-ils la fièvre ?\nQuels effets secondaires peuvent survenir avec les COX-2 ?\nLes COX-2 affectent-ils l'humeur ?\nPeut-on ressentir des douleurs abdominales avec les COX-2 ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Neural+Cell+Adhesion+Molecule+L1&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inhibiteurs de la cyclooxygénase 2", "description": "Comment prévenir les effets secondaires des COX-2 ?\nY a-t-il des mesures préventives avant de commencer les COX-2 ?\nLes patients à risque doivent-ils éviter les COX-2 ?\nComment surveiller l'efficacité des COX-2 ?\nLes changements de mode de vie aident-ils avec les COX-2 ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Neural+Cell+Adhesion+Molecule+L1&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inhibiteurs de la cyclooxygénase 2", "description": "Quels médicaments sont des inhibiteurs de COX-2 ?\nComment les COX-2 sont-ils administrés ?\nLes COX-2 peuvent-ils être combinés avec d'autres médicaments ?\nQuelle est la durée du traitement avec les COX-2 ?\nLes COX-2 sont-ils disponibles sans ordonnance ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Neural+Cell+Adhesion+Molecule+L1&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inhibiteurs de la cyclooxygénase 2", "description": "Quelles complications peuvent survenir avec les COX-2 ?\nLes COX-2 augmentent-ils le risque d'accidents vasculaires ?\nComment gérer les complications des COX-2 ?\nLes complications sont-elles fréquentes avec les COX-2 ?\nQuels signes indiquent une complication avec les COX-2 ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Neural+Cell+Adhesion+Molecule+L1&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inhibiteurs de la cyclooxygénase 2", "description": "Quels facteurs augmentent le risque d'effets secondaires des COX-2 ?\nL'âge influence-t-il le risque avec les COX-2 ?\nLes femmes enceintes peuvent-elles utiliser des COX-2 ?\nLe tabagisme affecte-t-il l'utilisation des COX-2 ?\nLes antécédents familiaux influencent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Neural+Cell+Adhesion+Molecule+L1&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une inflammation nécessitant des COX-2 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic repose sur l'examen clinique et des tests d'imagerie pour évaluer l'inflammation." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'efficacité des COX-2 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des échelles de douleur et des tests fonctionnels peuvent être utilisés pour évaluer l'efficacité." } }, { "@type": "Question", "name": "Les COX-2 sont-ils prescrits pour toutes les douleurs ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils sont généralement prescrits pour des douleurs inflammatoires spécifiques comme l'arthrite." } }, { "@type": "Question", "name": "Comment différencier les douleurs inflammatoires des autres ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les douleurs inflammatoires sont souvent accompagnées de raideur matinale et d'enflure." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent l'utilisation des COX-2 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'enflure, la chaleur et la douleur persistante peuvent indiquer leur utilisation." } }, { "@type": "Question", "name": "Quels symptômes traitent les inhibiteurs de COX-2 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Ils traitent principalement la douleur et l'inflammation associées à des conditions comme l'arthrite." } }, { "@type": "Question", "name": "Les COX-2 soulagent-ils la fièvre ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, les inhibiteurs de COX-2 ne sont pas principalement utilisés pour traiter la fièvre." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent survenir avec les COX-2 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent des troubles gastro-intestinaux, des maux de tête et des vertiges." } }, { "@type": "Question", "name": "Les COX-2 affectent-ils l'humeur ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Ils ne sont pas connus pour affecter directement l'humeur, mais la douleur chronique peut le faire." } }, { "@type": "Question", "name": "Peut-on ressentir des douleurs abdominales avec les COX-2 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs abdominales peuvent survenir en raison d'effets secondaires gastro-intestinaux." } }, { "@type": "Question", "name": "Comment prévenir les effets secondaires des COX-2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Pour prévenir les effets secondaires, il est conseillé de les prendre avec de la nourriture et de suivre les doses prescrites." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives avant de commencer les COX-2 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un bilan de santé et une évaluation des antécédents médicaux sont recommandés." } }, { "@type": "Question", "name": "Les patients à risque doivent-ils éviter les COX-2 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents de problèmes cardiaques doivent consulter un médecin avant de les utiliser." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité des COX-2 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "La surveillance peut inclure des évaluations régulières de la douleur et des tests de laboratoire." } }, { "@type": "Question", "name": "Les changements de mode de vie aident-ils avec les COX-2 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain peut améliorer l'efficacité des traitements anti-inflammatoires." } }, { "@type": "Question", "name": "Quels médicaments sont des inhibiteurs de COX-2 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des exemples incluent le célécoxib et le rofécoxib, utilisés pour traiter l'inflammation." } }, { "@type": "Question", "name": "Comment les COX-2 sont-ils administrés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont généralement administrés par voie orale sous forme de comprimés ou de capsules." } }, { "@type": "Question", "name": "Les COX-2 peuvent-ils être combinés avec d'autres médicaments ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, mais il est important de consulter un médecin pour éviter les interactions médicamenteuses." } }, { "@type": "Question", "name": "Quelle est la durée du traitement avec les COX-2 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La durée dépend de la condition traitée, mais elle doit être déterminée par un médecin." } }, { "@type": "Question", "name": "Les COX-2 sont-ils disponibles sans ordonnance ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Non, les inhibiteurs de COX-2 nécessitent généralement une prescription médicale." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les COX-2 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent inclure des problèmes gastro-intestinaux, des troubles cardiaques et des réactions allergiques." } }, { "@type": "Question", "name": "Les COX-2 augmentent-ils le risque d'accidents vasculaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains inhibiteurs de COX-2 peuvent augmenter le risque d'accidents vasculaires cérébraux." } }, { "@type": "Question", "name": "Comment gérer les complications des COX-2 ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une consultation médicale et un ajustement du traitement." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes avec les COX-2 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications ne sont pas fréquentes, mais elles peuvent survenir chez certains patients à risque." } }, { "@type": "Question", "name": "Quels signes indiquent une complication avec les COX-2 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs thoraciques, des saignements gastro-intestinaux ou des éruptions cutanées doivent alerter." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'effets secondaires des COX-2 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de maladies cardiaques, d'ulcères ou d'allergies augmentent le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque avec les COX-2 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent avoir un risque accru d'effets secondaires et de complications." } }, { "@type": "Question", "name": "Les femmes enceintes peuvent-elles utiliser des COX-2 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation des COX-2 pendant la grossesse doit être évitée sauf si prescrite par un médecin." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il l'utilisation des COX-2 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter le risque de complications gastro-intestinales avec les COX-2." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies cardiaques peuvent augmenter le risque d'effets secondaires." } } ] } ] }

Sources (10000 au total)

Analysis of L1CAM gene mutation and imaging appearance in three Chinese families with L1 syndrome: Three case reports.

The molecular mutations of the L1CAM gene and the imaging appearances of four fetuses with L1 syndrome from three independent Chinese families with a history of hydrocephalus were reported in this stu... Results of clinical and imaging examinations of three Chinese families were collected. Fetal samples were collected by puncture, genomic DNA was extracted, whole-exome sequencing was performed, and th... In this case report, we described the imaging appearance and investigated the mutations of the L1CAM gene in three Chinese families with a history of L1 syndrome; these included two nonsense mutations... The current study emphasizes the importance of combining family history, prenatal ultrasonography, and L1CAM mutation testing positive for the diagnosis of the L1 syndrome....

Increased expression of cell adhesion molecules in myofasciitis.

Myofasciitis is a heterogeneous group of diseases pathologically characterized by inflammatory cell infiltration into the fascia. Endothelial activation plays a critical role in the pathogenesis of th... Data on clinical features, thigh magnetic resonance imaging, and muscle pathology were collected from five patients with myofasciitis. Immunohistochemical (IHC) staining and Western blot (WB) of the m... Increased levels of serum pro-inflammatory cytokines, including IL-6, TNF-α, and IL-2R, were detected in four patients. IHC staining and WB indicated significantly increased expression of cell adhesio... The up-regulation of CAMs in myofasciitis indicates endothelial activation, which may be potential therapy targets for the treatment of myofasciitis....

The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.

To assess the risk stratification of clinicopathologically and molecularly classified endometrial cancer based on estrogen receptor (ER) and L1 cell adhesion molecule (L1CAM) expression.... This was a retrospective study of patients who underwent primary treatment at a single tertiary center. Carcinomas were classified into 5 clinicopathological risk groups, as per European guidelines. I... Data from 1044 patients were analyzed. The median follow-up was 67.5 months. In univariable analyses, ER expression correlated with improved disease-specific survival (DSS) in the "no specific molecul... The prognostic significance of ER and L1CAM varies across clinicopathological risk groups and molecular subgroups of endometrial cancer. Notably, risk assessment for high-risk-advanced-metastatic NSMP...

Neural cell adhesion molecule 1 is a cellular target engaged plasma biomarker in demyelinating Charcot-Marie-Tooth disease.

Elevated plasma concentrations of neural cell adhesion molecule 1 (NCAM1) and p75 neurotrophin receptor (p75) in patients with peripheral neuropathy have been reported. This study aimed to determine t... Blood samples were collected from 138 patients with inherited peripheral neuropathy and 51 healthy controls. Disease severity was measured using Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNSv2... Plasma concentration of NCAM1, but not p75, was specifically increased in demyelinating subtypes of CMT (median = 7100 pg/mL, p < 0.001), including CMT1A, but not in axonal subtype (5964 pg/mL, p > 0.... The plasma NCAM1 levels in demyelinating CMT might be a surrogate biomarker reflecting pathological Schwann cell status and disease progression....

Ubiquitous Neural Cell Adhesion Molecule (NCAM): Potential Mechanism and Valorisation in Cancer Pathophysiology, Drug Targeting and Molecular Transductions.

Neural cell adhesion molecule, an integrated molecule of immunoglobulin protein superfamily involved in cell-cell adhesion, undergoes various structural modifications through numerous temporal-spatial...

Associations of Circulating Vascular Cell Adhesion Molecule-1 and Intercellular Adhesion Molecule-1 With Long-Term Cardiac Function.

Although VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) have been associated with incident heart failure with preserved ejection fraction (HFpEF) and atrial ... In MESA (Multi-Ethnic Study of Atherosclerosis), we evaluated the associations of circulating VCAM-1 and ICAM-1 at examination 2 (2002-2004) with measures of cardiac structure/function on cardiac magn... Higher VCAM-1 and ICAM-1 were associated with lower LA function and left ventricular systolic function but were not associated with myocardial scar or interstitial fibrosis. VCAM-1 and ICAM-1 may prom...